363 related articles for article (PubMed ID: 11313285)
1. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect.
Schmaltz C; Alpdogan O; Horndasch KJ; Muriglan SJ; Kappel BJ; Teshima T; Ferrara JL; Burakoff SJ; van den Brink MR
Blood; 2001 May; 97(9):2886-95. PubMed ID: 11313285
[TBL] [Abstract][Full Text] [Related]
2. Major histocompatibility complex-mismatched allogeneic bone marrow transplantation using perforin and/or Fas ligand double-defective CD4(+) donor T cells: involvement of cytotoxic function by donor lymphocytes prior to graft-versus-host disease pathogenesis.
Jiang Z; Podack E; Levy RB
Blood; 2001 Jul; 98(2):390-7. PubMed ID: 11435308
[TBL] [Abstract][Full Text] [Related]
3. T-cell subsets mediate graft-versus-myeloid leukemia responses via different cytotoxic mechanisms.
Hsieh MH; Patterson AE; Korngold R
Biol Blood Marrow Transplant; 2000; 6(3):231-40. PubMed ID: 10871148
[TBL] [Abstract][Full Text] [Related]
4. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation.
Tsukada N; Kobata T; Aizawa Y; Yagita H; Okumura K
Blood; 1999 Apr; 93(8):2738-47. PubMed ID: 10194454
[TBL] [Abstract][Full Text] [Related]
5. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
Fowler DH; Gress RE
Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
[TBL] [Abstract][Full Text] [Related]
6. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
[TBL] [Abstract][Full Text] [Related]
7. Graft-versus-host-disease-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function, but not perforin function.
Baker MB; Riley RL; Podack ER; Levy RB
Proc Natl Acad Sci U S A; 1997 Feb; 94(4):1366-71. PubMed ID: 9037059
[TBL] [Abstract][Full Text] [Related]
8. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
[TBL] [Abstract][Full Text] [Related]
9. Donor T cells lacking Fas ligand and perforin retain the capacity to induce severe GvHD in minor histocompatibility antigen mismatched bone-marrow transplantation recipients.
Marks L; Altman NH; Podack ER; Levy RB
Transplantation; 2004 Mar; 77(6):804-12. PubMed ID: 15077018
[TBL] [Abstract][Full Text] [Related]
10. The contribution of cytotoxic and noncytotoxic function by donor T-cells that support engraftment after allogeneic bone marrow transplantation.
Jiang Z; Adams GB; Hanash AM; Scadden DT; Levy RB
Biol Blood Marrow Transplant; 2002; 8(11):588-96. PubMed ID: 12463477
[TBL] [Abstract][Full Text] [Related]
11. Differential use of FasL- and perforin-mediated cytolytic mechanisms by T-cell subsets involved in graft-versus-myeloid leukemia responses.
Hsieh MH; Korngold R
Blood; 2000 Aug; 96(3):1047-55. PubMed ID: 10910921
[TBL] [Abstract][Full Text] [Related]
12. Interleukin 18 preserves a perforin-dependent graft-versus-leukemia effect after allogeneic bone marrow transplantation.
Reddy P; Teshima T; Hildebrandt G; Duffner U; Maeda Y; Cooke KR; Ferrara JL
Blood; 2002 Nov; 100(9):3429-31. PubMed ID: 12384449
[TBL] [Abstract][Full Text] [Related]
13. Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease.
Pan L; Teshima T; Hill GR; Bungard D; Brinson YS; Reddy VS; Cooke KR; Ferrara JL
Blood; 1999 Jun; 93(12):4071-8. PubMed ID: 10361103
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.
Shustov A; Nguyen P; Finkelman F; Elkon KB; Via CS
J Immunol; 1998 Sep; 161(6):2848-55. PubMed ID: 9743345
[TBL] [Abstract][Full Text] [Related]
15. Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease.
Zheng H; Matte-Martone C; Li H; Anderson BE; Venketesan S; Sheng Tan H; Jain D; McNiff J; Shlomchik WD
Blood; 2008 Feb; 111(4):2476-84. PubMed ID: 18045967
[TBL] [Abstract][Full Text] [Related]
16. Antigen-primed CD8+ T cells can mediate resistance, preventing allogeneic marrow engraftment in the simultaneous absence of perforin-, CD95L-, TNFR1-, and TRAIL-dependent killing.
Komatsu M; Mammolenti M; Jones M; Jurecic R; Sayers TJ; Levy RB
Blood; 2003 May; 101(10):3991-9. PubMed ID: 12521999
[TBL] [Abstract][Full Text] [Related]
17. Both perforin and Fas ligand are required for the regulation of alloreactive CD8+ T cells during acute graft-versus-host disease.
Maeda Y; Levy RB; Reddy P; Liu C; Clouthier SG; Teshima T; Ferrara JL
Blood; 2005 Mar; 105(5):2023-7. PubMed ID: 15466930
[TBL] [Abstract][Full Text] [Related]
18. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice.
Baker MB; Altman NH; Podack ER; Levy RB
J Exp Med; 1996 Jun; 183(6):2645-56. PubMed ID: 8676085
[TBL] [Abstract][Full Text] [Related]
19. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
Fowler DH; Breglio J; Nagel G; Eckhaus MA; Gress RE
J Immunol; 1996 Dec; 157(11):4811-21. PubMed ID: 8943383
[TBL] [Abstract][Full Text] [Related]
20. Fas ligand-deficient gld mice are more susceptible to graft-versus-host-disease.
van den Brink MR; Moore E; Horndasch KJ; Crawford JM; Murphy GF; Burakoff SJ
Transplantation; 2000 Jul; 70(1):184-91. PubMed ID: 10919598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
